Secondary Logo

Journal Logo

CONCISE COMMUNICATION

High soluble CD163 levels correlate with disease progression and inflammation in Kenyan children with perinatal HIV-infection

Generoso, Matthewa; Álvarez, Patriciaa; Kravietz, Adama; Mwamzuka, Mussab; Marshed, Fatmab; Ahmed, Aabidb; Khaitan, Alkaa,c

Author Information
doi: 10.1097/QAD.0000000000002378

Abstract

Introduction

Globally, there are 37.9 million people living with HIV, of which 1.7 million are children [1]. With successful antiretroviral drugs, the major cause of HIV-related morbidity and mortality has shifted to non-AIDS complications, including cardiovascular disease and neurocognitive dysfunction [2,3]. These comorbidities are intricately linked to immune activation which begins early in HIV infection due to gut mucosal CD4+ T-cell destruction allowing microbial products to filter into systemic circulation and trigger immune responses mediated by monocytes and macrophages [4–8]. The subsequent chronic inflammation in the innate and adaptive immune systems drives HIV disease progression.

CD163 is a hemoglobin (Hb) scavenger receptor expressed primarily on monocytes and macrophages [4,9]. Upon activation from exposure to proinflammatory stimuli such as lipopolysaccharide, Fcγ receptor crosslinking or oxidative stress, membrane-bound CD163 sheds via proteinase-mediated cleavage as soluble CD163 (sCD163) [9]. Thus, plasma levels of sCD163 reflect nonspecific monocyte and macrophage activation [4,10]. Membrane-bound CD163 endocytoses haptoglobin–Hb complexes and plays a role in erythroblast adhesion and immune sensing of bacteria [4,9]. The function of sCD163 is undefined but has been proposed to be involved in inhibition of lymphocyte proliferation [9,11,12]. As an Hb scavenger sCD163 also plays an important role in extracellular iron recycling, which inhibits growth of iron-dependent bacterial pathogens [4,13,14].

HIV+ adults have elevated plasma sCD163 levels that persist despite antiretroviral treatment (ART) [4,15–18]. High sCD163 plasma concentrations directly correlate with the presence and progression of carotid artery atherosclerosis, noncalcified coronary plaques, and coronary artery stenosis [10,15,18–20]. In both human and nonhuman primate studies, monocyte activation is also associated with HIV neuropathogenesis [21,22]. Most importantly, sCD163 predicts all-cause mortality in adults [10]. Thus, in adults, plasma sCD163 levels serve as a biomarker of HIV-related morbidity and mortality.

In children, the early onset of inflammation during immunologic and neurologic development leads to additional long-term comorbidities such as delayed cognitive development and early onset cardiovascular disease [23–26], yet there are limited data on plasma sCD163 levels in the pediatric population [27–29]. In a cohort of perinatally-infected HIV+ Kenyan children aged 0–20 years, we report elevated sCD163 plasma concentrations that normalize to levels similar to HIV negative age-matched controls. High sCD163 plasma levels correlate with advancing HIV disease, gut mucosal disruption, and CD4+ and CD8+ T-cell activation, as well as CD4+ T-cell proliferation.

Materials and methods

Participants

Ethical approval for this study was obtained from New York University and Kenyatta National Hospital/University of Nairobi. Written informed consent and verbal assent was obtained from all participants and/or parents. We enrolled 138 perinatally infected HIV+ and 79 HIV negative-unexposed children (HIV−) ages 2 months to 20 years from Bomu Hospital in Mombasa, Kenya between 2011 and 2012. HIV+ children included 74 ART naïve (ART−) and 64 on ART for at least 6 months (ART+). Individuals with a recent pregnancy or acute illness or active Mycobacterium tuberculosis or malaria infection were ineligible for study entry.

Participants were subdivided into age groups of 0–5 (0–5 years or younger) and 5–20 (5–20 years or older) years old based on immunologic maturity. In both age cohorts HIV−, ART−, and ART+ were matched for age and sex (Table 1).

Table 1
Table 1:
Subject characteristics.

Plasma assays

Plasma levels of sCD163 and Intestinal Fatty Acid Binding Protein (I-FABP) were quantified by an enzyme-linked immunosorbent assay (ELISA) using Human sCD163 and I-FABP Duoset kits (R&D Systems, Minneapolis, Minnesota, USA). Plasma samples were diluted 1 : 100 for sCD163 and 1 : 1500 for I-FABP assays based on titration assays to fit within the standard curve range. Testing was performed in duplicate with average of duplicate results reported.

Flow cytometric studies

Cryopreserved peripheral blood mononuclear cells were thawed then evaluated with flow cytometry as described previously [30]. For intracellular cytokine staining, cells were activated with phorbol-myristate acetate and Ionomicin in the presence of monensin for 5 h, then fixed, permeabilized (eBioscience, San Diego, California, USA) and stained with intracellular antibodies. The following antihuman antibodies were used: CD3, CD4+, CD8+, CD45RO, CD38, human leukocyte antigen-DR isotype (HLA-DR), Ki67, and IL-2. Stained cells were analyzed using LSRII flow cytometer (BD Bioscience, San Jose, California, USA) and FlowJo software (Tree Star, Ashland, Oregon, USA).

Statistical analysis

All statistical analyses were performed using GraphPad Prism software. Comparisons between multiple groups were performed with the Kruskal–Wallis followed by the two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli to correct for multiple comparisons by controlling the False Discovery Rate. Multiple time points were evaluated with Wilcoxon matched-pairs signed-rank test. Correlations were assessed with the Spearman rank test. Threshold of significance for all tests was 0.05.

Results

High plasma soluble CD163 levels in antiretroviral treatment− children normalize with treatment

Plasma sCD163 levels were higher in ART−0–5 years than HIV−0–5 years (P = 0.004; Fig. 1a1) and ART+0–5 years (P = 0.01; Fig. 1a1). In the older cohort, ART−5–20 years also had higher plasma sCD163 levels than HIV−5–20 years (P < 0.0001; Fig. 1a2) and ART+5–20 years (P < 0.0001; Fig. 1a2). In a subset of ART− children who initiated treatment, after ∼12 months of treatment, plasma sCD163 levels remained stable in ART−0–5 years children (Fig. 1a3 and a5) and decreased in ART−5–20 years children (P < 0.0001; Fig. 1a4) to levels similar to HIV−5–20 years children (Fig. 1a6).

Fig. 1
Fig. 1:
Soluble CD163 levels in HIV-infected children.Children aged 0–5 years are shown in red and 5–20 years in blue. (a) Left (a1 and a2): comparison of plasma soluble CD163 concentrations in HIV unexposed-uninfected (HIV−), HIV-infected untreated (antiretroviral treatment−), and HIV-infected treated (antiretroviral treatment+) children. Center (a3 and a4): plasma soluble CD163 levels in antiretroviral treatment− children who began treatment before (T0) and 12 months after (T1) treatment initiation. Right (a5 and a6): comparison between soluble CD163 levels in antiretroviral treatment− at T0 and T1 and HIV− children. (b) Correlation between plasma soluble CD163 concentrations and HIV viral load (b1 and b2), percentage CD4+ T cells (b3 and b4), and CD4+ : CD8+ ratio (b5 and b6) in HIV+ children. Correlation between plasma soluble CD163 concentrations and (c) percentage of CD38+HLA-DR+ (human leukocyte antigen-DR isotype) cells on CD4+ (c1 and c2) and CD8+ (c3 and c4) T cells, (d) Ki67 (d1 and d2) and IL-2 (d3 and d4) levels in CD45RO+ CD4+ T cells, and (e) plasma intestinal fatty acid binding protein (e1 and e2) and soluble CD14 (e3 and e4) levels in HIV+ children.

Increased plasma soluble CD163 levels correlate with HIV disease progression

To determine the clinical relevance of elevated sCD163 plasma levels, we examined correlations between sCD163 and clinical markers of HIV disease progression. In HIV+0–5 years children, plasma sCD163 levels directly correlated with HIV viral load (P = 0.004, r = 0.37; Fig. 1b1) and inversely correlated with %CD4+ (P = 0.003, r = −0.39; Fig. 1b3) and CD4+ : CD8+ ratios (P = 0.02, r = −0.32; Fig. 1b5). In HIV+5–20 years children, plasma sCD163 levels correlated directly with viral load (P < 0.0001, r = 0.57; Fig. 1b2) and inversely with %CD4+ (P = 0.004, r = −0.32; Fig. 1b4) and CD4+ : CD8+ ratios (P = 0.007, r = −0.30; Fig. 1b6).

Plasma soluble CD163 levels correlate with immune activation and gut mucosal disruption

Coexpression of CD38 and HLA-DR marks T-cell activation and predicts HIV disease progression. We investigated their correlations with sCD163 (Fig S1, http://links.lww.com/QAD/B538: gating strategy for CD38+HLA-DR+ T cells). In HIV+0–5 years children, plasma sCD163 levels directly correlate with CD38+HLA-DR+ CD4+ T cells (P = 0.01, r = 0.36; Fig. 1c1) and CD8+ T cells (P = 0.005, r = 0.39; Fig. 1c3). These correlations were similarly observed in HIV+5–20 years children (CD4+: P < 0.0001, r = 0.43; CD8+: P = 0.008, r = 0.29; Fig. 1c2 and c4). We also determined whether sCD163 links to CD4+ T-cell proliferation by examining associations with Ki67, a marker of activated T-cell proliferation, and IL-2, a cytokine that maintains homeostatic T-cell proliferation. Plasma sCD163 concentrations directly correlated with Ki67 levels in memory CD4+ T cells (P = 0.003, r = 0.40; Fig. 1d1) but not with IL-2 in HIV+0–5 years children (Fig. 1d3). In HIV+5–20 years children, sCD163 directly correlated with Ki67 (P = 0.0009, r = 0.37; Fig. 1d2) and inversely correlated with IL-2 levels in memory CD4+ T cells (P < 0.0001, r = −0.44; Fig. 1d4).

We next investigated the relationship between plasma levels of sCD163 and I-FABP, a marker of gut mucosal disruption. In the HIV+0–5 years children, there was no association between these markers (Fig. 1e1), but in HIV+5–20 years children there was a significant direct correlation (P = 0.02, r = 0.27; Fig. 1e2). Last, we investigated whether sCD163 is associated with another monocyte activation marker, soluble CD14. A direct correlation between the two markers was observed in the HIV+0–5 years children (P = 0.0006, r = 0.43; Fig. 1e3), but no correlation was present in the HIV+5–20 years children (Fig. 1e4).

Discussion

We demonstrated that plasma sCD163 levels are elevated in untreated HIV+ children beginning in early childhood. In both age cohorts, ART+ children have sCD163 levels similar to HIV− controls. Regardless of age, higher plasma sCD163 levels correlate with worsening disease status, measured by decreasing CD4+ T-cell percentage and CD4+ : CD8+ ratio, and increasing HIV viral load. Finally, sCD163 plasma concentrations in HIV+ children correlated with T-cell activation and CD4+ T-cell proliferation, suggesting a link between innate and adaptive immunity.

To our knowledge, this is the first report of sCD163 levels in a pediatric cohort aged less than 5 years old with direct comparison with an older cohort. Remarkably, young children exhibited elevation of sCD163 levels similar to older children. Prior studies of sCD163 in HIV+ children include children with median age above 6 years and report high plasma sCD163 levels that decrease with ART. Anaworanich et al. demonstrate, in a Thai cohort with median age 6 years, that sCD163 levels in ART+ children were lower than ART− children [29]. Tuluc et al.[28] report, in children aged 9–18 years, that plasma sCD163 levels significantly decrease after treatment with Raltegravir. However, these two studies lack an HIV− control group to evaluate whether sCD163 plasma levels normalize. In our cohort, younger and older children normalized sCD163 levels in both cross-sectional and prospective analyses. Rudy et al.[27] show that plasma sCD163 levels significantly decrease after 48 weeks of ART, but remain significantly higher than HIV− controls, as opposed to our observation of similar sCD163 concentrations in ART+ and HIV− children. We speculate the discrepancy may reflect different age cohorts, as the findings of Rudy et al. [27] in HIV+ youth aged 18–25 years match previous adult sCD163 studies of persistently high sCD163 levels after treatment. It is possible that, after a certain age, it is no longer possible to reverse monocyte activation. Thus, in children, there may be a critical window to initiate ART to partially reverse monocyte activation.

In HIV+ adults, sCD163 remains increased despite ART [4,15–18]. These high sCD163 plasma levels have been linked to mortality, as demonstrated by Knudsen et al.[10] in a study of 933 virally suppressed HIV-infected adults in Denmark. With each milligram per liter increase in sCD163, there was a 6% increase in mortality [10]. Significantly, plasma sCD163 levels were not predictive of mortality in untreated HIV infection, when active HIV replication drives inflammation. Rather, they were only predictive for virally suppressed individuals whose inflammation is likely due to microbial translocation, coinfections or low-level replication of viral reservoirs [10]. While sCD163 levels were linked to all-cause mortality, the predictive value was slightly higher for cardiovascular causes of death [10,31]. Whether sCD163 levels are linked to cardiovascular disease and mortality in children is unknown. We demonstrate that high plasma sCD163 concentrations correlate with worsening disease status, indicated by viremia, T-cell activation, and decreasing CD4+ percentages and CD4+ : CD8+ ratios. In pediatric HIV, clinical parameters are associated with HIV-related morbidity while T-cell activation has been linked to increased risk of early onset cardiovascular disease and neurocognitive dysfunction. We speculate that monocyte activation may also be correlated with similar morbidity [23–26]. In adults, chronic inflammation is triggered by gut mucosal disruption. Significantly, in our cohort, plasma sCD163 levels associated with I-FABP levels in older but not younger children, suggesting there may be cumulative damage to the intestinal mucosa that triggers monocyte activation after longer durations of perinatal HIV infection.

In summary, we demonstrate high plasma sCD163 levels in perinatally infected HIV+ children that correlate with advancing HIV disease. Antiretroviral therapy reverses the elevation of plasma sCD163 levels within 12 months. Plasma sCD163 concentrations correlate with T-cell activation and proliferation, linking inflammation in the innate and adaptive immune systems. Early evidence of reversible monocyte activation in children supports the urgent implantation of immediate ART initiation in children as recommended by the WHO to alleviate the global burden of complications secondary to HIV infection and improve overall pediatric health outcomes.

Acknowledgements

We thank all of the children and families who participated in this study.

Authors’ contributions: M.G. performed sCD163 ELISA assays, analyzed data and drafted the article and figures. P.A. performed I-FABP ELISA assay. A.K.r. performed immune phenotyping studies and analyzed flow cytometry data. M.M. collected and processed blood samples, performed sCD14 ELISA assays and managed data. F.M. recruited patients and recorded clinical data. A.A. provided input to study design and oversaw recruitment site. A.K.h. conceptualized and supervised the study, designed experiments, interpreted data and edited the article.

The current study was funded by NIH grant 5K08AI093235-02 to A.K. It was also supported by Centers for Disease Control and Prevention (CDC) Cooperative Agreement (5U2GPS002063-03). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.

Conflicts of interest

There are no conflicts of interest.

References

1. Fact Sheet - Global AIDS Update 2019. UNAIDS. 2019. aidsinfo.unaids.org.
2. Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, et al. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis 2014; 210:1396–1406.
3. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841–848.
4. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204:154–163.
5. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365–1371.
6. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3:e2516.
7. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614–622.
8. Musselwhite LW, Sheikh V, Norton TD, Rupert A, Porter BO, Penzak SR, et al. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS 2011; 25:787–795.
9. Moller HJ. Soluble CD163 Scandinavian. J Clin Lab Investig 2012; 72:1–13.
10. Knudsen TB, Ertner G, Petersen J, Moller HJ, Moestrup SK, Eugen-Olsen J, et al. Plasma soluble CD163 level independently predicts all-cause mortality in HIV-1-infected individuals. J Infect Dis 2016; 214:1198–1204.
11. Frings W, Dreier J, Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett 2002; 526:93–96.
12. Hogger P, Sorg C. Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochem Biophys Res Commun 2001; 288:841–843.
13. Madsen M, Moller HJ, Nielsen MJ, Jacobsen C, Graversen JH, van den Berg T, et al. Molecular characterization of the haptoglobin.hemoglobin receptor CD163. Ligand binding properties of the scavenger receptor cysteine-rich domain region. J Biol Chem 2004; 279:51561–51567.
14. Weaver LK, Hintz-Goldstein KA, Pioli PA, Wardwell K, Qureshi N, Vogel SN, et al. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 2006; 80:26–35.
15. Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227–1236.
16. O’Halloran JA, Dunne E, Gurwith M, Lambert JS, Sheehan GJ, Feeney ER, et al. The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection. HIV Med 2015; 16:608–619.
17. Beltran LM, Munoz Hernandez R, de Pablo Bernal RS, Garcia Morillo JS, Egido J, Noval ML, et al. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One 2014; 9:e90541.
18. McKibben RA, Margolick JB, Grinspoon S, Li X, Palella FJ Jr, Kingsley LA, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis 2015; 211:1219–1228.
19. Fitch KV, Srinivasa S, Abbara S, Burdo TH, Williams KC, Eneh P, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208:1737–1746.
20. Hanna DB, Lin J, Post WS, Hodis HN, Xue X, Anastos K, et al. Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men. J Infect Dis 2017; 215:1352–1361.
21. Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, Sugimoto C, et al. Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog 2010; 6:e1000842.
22. Fischer-Smith T, Bell C, Croul S, Lewis M, Rappaport J. Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J Neurovirol 2008; 14:318–326.
23. Alvarez P, Mwamzuka M, Marshed F, Kravietz A, Ilmet T, Ahmed A, et al. Immune activation despite preserved CD4 T cells in perinatally HIV-infected children and adolescents. PLoS One 2017; 12:e0190332.
24. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236–1243.
25. Pilakka-Kanthikeel S, Huang S, Fenton T, Borkowsky W, Cunningham CK, Pahwa S. Increased gut microbial translocation in HIV-infected children persists in virologic responders and virologic failures after antiretroviral therapy. Pediatr Infect Dis J 2012; 31:583–591.
26. Willen EJ, Cuadra A, Arheart KL, Post MJ, Govind V. Young adults perinatally infected with HIV perform more poorly on measures of executive functioning and motor speed than ethnically matched healthy controls. AIDS Care 2017; 29:387–393.
27. Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, et al. Immune reconstitution but persistent activation after 48 weeks of antiretroviral therapy in youth with pre-therapy CD4 >350 in ATN 061. J Acquir Immune Defic Syndr 2015; 69:52–60.
28. Tuluc F, Spitsin S, Tustin NB, Murray JB, Tustin R 3rd, Schankel LA, et al. Decreased PD-1 expression on CD8 lymphocyte subsets and increase in CD8 Tscm cells in children with HIV receiving raltegravir. AIDS Res Hum Retroviruses 2017; 33:133–142.
29. Ananworanich J, Kerr SJ, Jaimulwong T, Vibol U, Hansudewechakul R, Kosalaraksa P, et al. Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children. J Virus Erad 2015; 1:196–202.
30. Foldi J, Kozhaya L, McCarty B, Mwamzuka M, Marshed F, Ilmet T, et al. HIV-infected children have elevated levels of PD-1+ memory CD4 T cells with low proliferative capacity and high inflammatory cytokine effector functions. J Infect Dis 2017; 216:641–650.
31. Hunt PW. Soluble CD163 and clinical outcomes in treated HIV infection: insights into mechanisms. J Infect Dis 2016; 214:1132–1133.
Keywords:

children; HIV; immune activation; intestinal fatty acid binding protein; soluble CD163

Supplemental Digital Content

Copyright © 2020 Wolters Kluwer Health, Inc.